Keyphrases
Schizophrenia
100%
Long-acting Injectable
100%
Injectable Drugs
100%
Risperidone
89%
Trial Network
73%
Patients with Schizophrenia
71%
Long-acting Preparation
50%
New Drugs
36%
Atypical Antipsychotics
36%
Objective Comparison
36%
Schizoaffective Disorder
36%
Psychopathology
18%
Network Infrastructure
18%
Successful Implementation
18%
Unit Management
18%
Adverse Events
18%
Time Monitoring
18%
Blinded Treatment
18%
Long-acting Injectable Antipsychotics
18%
Service Utilization
18%
Fast Startup
18%
Glucose-insulin System
18%
Politicians
18%
Efficient Data Analysis
18%
Primary Outcome Measure
18%
Tolerability
18%
Wholesale Price
18%
Manuscript Preparation
18%
Premium Price
18%
Time to Relapse
18%
Oral Antipsychotics
18%
Repeated Assessment
18%
Clinical Setting
18%
Fluphenazine Decanoate
18%
Lipids
18%
Paliperidone Palmitate
18%
Clinical Practice
18%
Olanzapine Pamoate
18%
High-quality Data
18%
Market Saturation
18%
Aggressive Marketing
18%
Prolactin
18%
Data Management
18%
Psychotic Relapse
16%
New Preparations
16%
Antipsychotics
16%
Public Health
8%
Pharmacology, Toxicology and Pharmaceutical Science
Microsphere
100%
Risperidone
100%
Schizoaffective Psychosis
41%
Atypical Antipsychotics
41%
Antipsychotic
37%
Typical Antipsychotic
20%
Fluphenazine Decanoate
20%
Tolerability
20%
Adverse Event
20%
Prolactin
20%
Paliperidone
20%
Olanzapine
20%
Nursing and Health Professions
Drug Therapy
50%
Risperidone
42%
Microsphere
42%
Schizoaffective Psychosis
14%
Atypical Antipsychotics
14%
Olanzapine
7%
Paliperidone
7%
Clinician
7%
Typical Antipsychotic
7%
Fluphenazine Decanoate
7%
Prolactin
7%
Cost Effectiveness Analysis
7%
Clinical Practice
7%
Adverse Event
7%